Orphenadrine

Half-Life (t½)
PO: 16.5h · IV: 16.5h
Formula
C18H23NO
Molecular Weight
269.39 g/mol
PubChem CID
4601
Aliases
Norflex

Pharmacological Mechanism

Anticholinergic + NMDA antagonist + weak NET inhibitor — centrally-acting muscle relaxant for acute musculoskeletal pain. Anticholinergic burden similar to cyclobenzaprine; Beers-list problematic.

Half-Life & Elimination Curve (PO: 16.5h · IV: 16.5h)

100%50%25%12.5%0%0h0×t½16.5h1×t½33h2×t½49.5h3×t½66h4×t½3.4d5×t½0×t½ (0h): 100% remaining (~0.196 mg/L)1×t½ (16.5h): 50% remaining (~97.9 µg/L)2×t½ (33h): 25% remaining (~49 µg/L)3×t½ (49.5h): 12.5% remaining (~24.5 µg/L)4×t½ (66h): 6.3% remaining (~12.2 µg/L)5×t½ (3.4d): 3.1% remaining (~6.12 µg/L)
Plasma (PO)t½ Decay (16.5h)
  • 0×t½0h100% (0.196 mg/L)
  • 1×t½16.5h50% (97.9 µg/L)
  • 2×t½33h25% (49 µg/L)
  • 3×t½49.5h12.5% (24.5 µg/L)
  • 4×t½66h6.3% (12.2 µg/L)
  • 5×t½3.4d3.1% (6.12 µg/L)
Elimination t½16.5h (PO)
Rate Constant (ke)0.042 h⁻¹
Time to Peak (Tmax)3.31h
Est. Peak (Cmax)0.196 mg/L
Clearance (CL)16.8 L/h
97% Washout (5×t½)3.4d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References